Search results for "testi"

showing 10 items of 4607 documents

Early stage human colorectal cancer: prognostic value of nm23-H1 protein overexpression

1997

Nm23 gene codifies for a nucleoside diphosphate kinase allowing the intracellular transduction of the signals. In colorectal cancer nm23 protein expression seems related to the progression of the disease. By immunohistochemistry we have studied the intracytoplasmatic nm23 H1 protein expression in 20 patients affected by colorectal cancer at initial stage. In 12 cases it resulted elevated and in four the disease recurred. The overexpression was not correlated with other prognostic factors. Nm23 H1-positive patients affected by colorectal cancer at initial stage could be considered at risk for disease recurrence and included in a more frequent follow-up protocol.

AdultMaleCancer ResearchPathologymedicine.medical_specialtyColorectal cancerRectumDiseaseMouse model of colorectal and intestinal cancerGene expressionBiomarkers TumormedicineCarcinomaHumansAgedMonomeric GTP-Binding ProteinsNeoplasm StagingAged 80 and overbusiness.industryMiddle AgedNM23 Nucleoside Diphosphate KinasesPrognosismedicine.diseaseNucleoside-diphosphate kinaseNeoplasm Proteinsmedicine.anatomical_structureOncologyNucleoside-Diphosphate KinaseDisease ProgressionCancer researchImmunohistochemistryFemaleColorectal NeoplasmsbusinessTranscription FactorsCancer Letters
researchProduct

[18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation

2003

The nucleoside 5-fluoro-2-deoxyuridine is a pyrimidine analogue accumulating in proliferative cells. We prospectively evaluated biodistribution of the PET tracer [(18)F]5-fluoro-2-deoxyuridine (FdUrd), its value for imaging malignant tumors, and its correlation to both [(18)F]2-fluoro-2-deoxyglucose (FDG)-PET findings and histological proliferation indices. In 11 previously untreated patients (5 lung carcinoma; 3 soft tissue sarcoma; 2 gastrointestinal carcinoma; 1 non-Hodgkin lymphoma [NHL]), mean doses of 290 MBq FdUrd and 390 MBq FDG were administered intravenously on subsequent days. Static PET scans were initiated 50-70 min after administration and the mean standardized uptake values (…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsProliferation indexUrinary BladderKidneyBone and BonesPyrimidine analogueFluorodeoxyglucose F18NeoplasmsmedicineCarcinomaHumansTissue DistributionRadiology Nuclear Medicine and imagingProspective StudiesAgedGastrointestinal NeoplasmsNeoplasm StagingPharmacologymedicine.diagnostic_testbusiness.industryLymphoma Non-HodgkinSoft tissue sarcomaKidney metabolismSarcomaGeneral MedicineMiddle Agedmedicine.diseaseLymphomaKi-67 AntigenLiverOncologyPositron emission tomographyFemaleSarcomaRadiopharmaceuticalsbusinessNuclear medicineCell DivisionTomography Emission-Computed
researchProduct

Array comparative genomic hybridization analysis of chromosomal imbalances and their target genes in gastrointestinal stromal tumors.

2007

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. The tumors characteristically harbor KIT or PDGFRA mutations, and mutant tumors respond to imatinib mesylate (Glivectrade mark). Chromosomal imbalances resulting in altered gene dosage are known to have a role in the molecular pathogenesis of these tumors, but the target genes remain to be identified. The present study aimed to identify some of these genes. In total, 35 GIST samples were screened for chromosomal imbalances by array-based comparative genomic hybridization. A cDNA array was used to define the minimal common overlapping areas of DNA copy number change. Eight confirmative, …

AdultMaleCancer ResearchStromal cellGastrointestinal Stromal TumorsGene DosageBiologyGenomeGene dosageGene FrequencyGeneticsmedicineNeoplasmChromosomes HumanHumansGeneAllele frequencyAgedOligonucleotide Array Sequence AnalysisGeneticsAged 80 and overChromosome AberrationsGenome HumanNucleic Acid HybridizationMiddle Agedmedicine.diseaseHuman geneticsFemaleComparative genomic hybridizationGenes NeoplasmGenes, chromosomescancer
researchProduct

Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study.

1990

Fifty patients affected by histologically confirmed gastrointestinal tract cancer (GTC) were treated with oral tegafur (TG) 1,000 mg m-2 p.o. on days 1-14 repeated after a 14 day interval. Out of 42 evaluable patients seven patients had a partial response (PR. 17%) with a median duration of 20.5 weeks, three had a minimal response (7%) with a median duration of 23.7 weeks, nine showed a stabilisation which lasted a median of 31.3 weeks, and 23 progressed (55%). No response was obtained in patients affected by carcinoma of the pancreas and the hepatobiliary system. All PRs were achieved in patients with metastatic disease to the liver. No response was seen in patients with bone, lung or noda…

AdultMaleCancer Researchmedicine.medical_specialtyNauseamedicine.medical_treatmentPhases of clinical researchAdministration OralTegafurGastroenterologyStomach NeoplasmsInternal medicinemedicineCarcinomaHumansAgedTegafurChemotherapyGastrointestinal tractbusiness.industryStomachMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureOncologyVomitingDrug EvaluationFemalemedicine.symptombusinessColorectal Neoplasmsmedicine.drugResearch ArticleBritish Journal of Cancer
researchProduct

Weekly Levofolinic Acid and 5-Fluorouracil Plus Hydroxyurea in Metastatic Gastrointestinal Adenocarcinomas

1994

There were 42 patients with advanced gastrointestinal carcinomas (GA) enrolled in the study. In the Phase I part of the study we identified the MTD of 5-fluorouracil (5FU) in combination with levofolinic acid 100 mg/m2 per week intravenously plus hydroxyurea 1 g/m2 per week given by mouth in 3 refracted doses starting 6 hours after 5FU was administered. This treatment was given weekly for 6 consecutive weeks followed by a 15-day rest period. We were not able to increase 5FU weekly dosage above 700 mg/m2 due to the occurrence of grade 3-4 gastrointestinal toxicity. Thus 5FU was employed at 600 mg/m2 per week for the Phase II part of the study. Among 20 evaluable patients with measurable meta…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentLeucovorinRectumAdenocarcinomaGastroenterologyAntimetaboliteDrug Administration ScheduleHydroxycarbamideInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHydroxyureaAgedGastrointestinal NeoplasmsChemotherapybusiness.industryMiddle AgedSurvival AnalysisSurgeryRegimenmedicine.anatomical_structureOncologyFluorouracilToxicityVomitingFemaleFluorouracilmedicine.symptombusinessmedicine.drugAmerican Journal of Clinical Oncology
researchProduct

Oligophrenin 1 mutations frequently cause X-linked mental retardation with cerebellar hypoplasia

2005

Background: Mutations of oligophrenin 1, one of the first genes identified in nonspecific X-linked mental retardation (MRX), have been described in patients with moderate to severe cognitive impairment and predominant cerebellar hypoplasia, in the vermis. Objective: To further delineate the phenotypic and mutational spectrum of the syndrome, by screening oligophrenin 1 in two cohorts of male patients with mental retardation (MR) with or without known posterior fossa anomalies. Methods: Clinical examination, cognitive testing, MRI studies, and mutational analysis (denaturing gradient gel electrophoresis and direct sequencing) on blood lymphocytes were performed in 213 unrelated affected indi…

AdultMaleCerebellumAdolescentGenotypeDNA Mutational AnalysisNonsense mutationNervous System Malformationsmedicine.disease_causeCohort StudiesExonCerebellar DiseasesCerebellummedicineHumansGenetic TestingChildCerebellar hypoplasiaGeneticsMutationSplice site mutationGTPase-Activating ProteinsNuclear Proteinsmedicine.diseaseMagnetic Resonance ImagingHypoplasiaPedigreeDevelopmental disorderAlternative SplicingCytoskeletal ProteinsPhenotypemedicine.anatomical_structureFacial AsymmetryCodon NonsenseChild PreschoolMutationMental Retardation X-LinkedRNA Splice SitesNeurology (clinical)PsychologyGene DeletionNeurology
researchProduct

Hsp60 and Hsp10 increase in colon mucosa of Crohn's disease and ulcerative colitis.

2010

The purpose of this work was to determine in colon mucosa of Crohn’s disease (CD) and ulcerative colitis (UC) in relapse: a) the levels of the chaperonins Hsp60 and Hsp10; b) the quantity of inflammatory cells; and c) if the levels of chaperonins parallel those of inflammation cells. Twenty cases of CD and UC and twenty normal controls (NC) were studied using immunohistochemistry, Western blotting and immunofluorescence. Immunohistochemically, Hsp60 and Hsp10 were increased in both inflammatory bowel diseases (IBD) compared to NC. These results were confirmed by Western blotting. Hsp60 and Hsp10 occurred in the cytoplasm of epithelial cells in CD and UC but not in NC. Hsp60 and Hsp10 co-loc…

AdultMaleColonConnective tissueInflammationBiologyBiochemistryImmune systemSettore MED/38 - Pediatria Generale E SpecialisticaCrohn DiseaseIntestinal mucosaChaperonin 10LeukocytesmedicineHumansIntestinal MucosaColitisIBD HSP 60 HSP 10AgedOriginal PaperLamina propriaCrohn's diseaseEpithelial CellsChaperonin 60Cell BiologyMiddle Agedmedicine.diseaseUlcerative colitismedicine.anatomical_structureImmunologyColitis UlcerativeFemalemedicine.symptom
researchProduct

Illness perception and affective symptoms in gastrointestinal cancer patients: A moderated mediation analysis of meaning in life and coping.

2019

Objective The character of the mediational relations between illness perception and affective symptoms often depends on the coping strategies used by patients. For example, these relationships may be moderated by meaning in life that plays a buffering role against the negative consequences of cancer. This study examined moderated mediation effects of meaning in life and coping on the relationship between illness perception and affective symptoms in cancer patients. Methods In this cross-sectional research, 317 gastrointestinal cancer patients who were undergoing chemotherapy, radiotherapy, or combined therapy treatments were examined. They completed measures of illness perception, affective…

AdultMaleCoping (psychology)Health Knowledge Attitudes Practicegenetic structuresExperimental and Cognitive PsychologyAffect (psychology)IrritabilityIllness perceptions03 medical and health sciences0302 clinical medicineModerated mediationAdaptation PsychologicalmedicineHumans030212 general & internal medicineGastrointestinal cancerAffective SymptomsAgedGastrointestinal NeoplasmsAged 80 and overMiddle AgedModerationmedicine.diseasePsychiatry and Mental healthCross-Sectional StudiesOncology030220 oncology & carcinogenesisCombined therapyFemalemedicine.symptomPsychologyClinical psychologyPsycho-oncology
researchProduct

Italian males recovering from mild COVID-19 show no evidence of SARS-CoV-2 in semen despite prolonged nasopharyngeal swab positivity.

2020

AdultMaleCoronavirus disease 2019 (COVID-19)Molecular biologyUrologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralViral transmissionSemenDiseasesRisk AssessmentBetacoronavirusCOVID-19 TestingSemenPandemicCorrespondenceDisease Transmission InfectiousMedicineHumansMolecular biology DiseasesPandemicsViral Epidemiologybusiness.industryClinical Laboratory TechniquesSARS-CoV-2Patient AcuityCOVID-19Patient AcuityMiddle Agedmedicine.diseaseVirologySemen AnalysisPneumoniaItalybusinessCoronavirus InfectionsInternational journal of impotence research
researchProduct

Qualitative assessment of SARS-CoV-2-specific antibody avidity by lateral flow immunochromatographic IgG/IgM antibody assay.

2020

Abstract Knowledge of the precise timing of SARS‐CoV‐2 infection may be of clinical and epidemiological relevance. The presence of low‐avidity IgGs has conventionally been considered an indicator of recent infection. Here, we carried out qualitative assessment of SARS‐CoV‐2‐specific antibody avidity using an urea (6M) dissociation test performed on a lateral flow immunochromatographic IgG/IgM device. We included a total of 76 serum specimens collected from 57 COVID‐19 patients, of which 39 tested positive for both IgG and IgM and 37 only for IgG. Sera losing IgG reactivity after urea treatment (n = 28) were drawn significantly earlier (P = .04) after onset of symptoms than those which prese…

AdultMaleCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Short CommunicationAntibody AffinityShort CommunicationsAntibodies ViralImmunoglobulin GSARS‐CoV‐2COVID-19 Serological Testing03 medical and health sciences0302 clinical medicineavidityVirologyurea dissociationMedicineHumansantibodiesIn patientAvidity030212 general & internal medicineQualitative ResearchAgedAged 80 and overImmunoassayCovid‐19medicine.diagnostic_testbiologybusiness.industrySARS-CoV-2COVID-19Middle AgedVirologySpecific antibodyInfectious DiseasesImmunoglobulin MImmunoglobulin MImmunoassayImmunoglobulin GImmunologybiology.protein030211 gastroenterology & hepatologyFemaleAntibodybusinessJournal of medical virology
researchProduct